MOCON Introduces Next Generation Oxygen Permeation Test System With Significant New Benefits Including Reduced Test Times
The new instrument is ideal for food, pharmaceutical, medical device and material producers who need to test packaging structures for oxygen permeation.
The new OX-TRAN® Model 2/22 H is a fully automated and extremely user-friendly system. With MOCON's advanced technology and design enhancements, test times are reduced significantly depending on barrier quality. In addition, the repeatability specification has been improved 2.5 times over the industry standard OX-TRAN Model 2/21 H.
Automation features include relative humidity, temperature, pressure, flow and testing which are simply set via the integrated and intuitive touch screen. Remote viewing and control from anywhere in the world is possible with the connectivity options. When testing film with unknown characteristics, the auto test feature determines the optimal parameters and conducts the test to completion. Sequential testing allows for a film to be tested at multiple temperature/relative humidity conditions with no operator involvement.
The OX-TRAN Model 2/22 H is designed to operate at a lower cost of ownership by eliminating several common maintenance costs. The install wizard allows for step-by-step user installation and the gas saver feature automatically reduces gas consumption when the system is idle. In addition, many safety features have been added to increase component lifetime.
"It is very difficult to accurately measure the trace amounts of oxygen transmitting through today's packaging materials. We believe the design of the OX-TRAN Model 2/22 H will go above and beyond the expectations of our customers, providing the high quality results they have come to rely on from MOCON," said Doug Lindemann, vice president, MOCON.
The new OX-TRAN Model 2/22 H will be available for demonstration at Interpack, May 8-14, Dusseldorf, Germany, Hall 5 Stand J03.
This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include but are not limited to: uncertainties relating to competition and technological change, setbacks in product development program, slower-than-anticipated customer acceptance of new products, dependence on certain key industries, risk associated with the Company's acquisition strategy and international operations, and other factors set forth in the Company's filing with the Securities and Exchange Commission.
MOCON is a leading provider of instrumentation and consulting and laboratory services to medical, pharmaceutical, food and other industries worldwide. See www.mocon.com for more information.
Press releases you might also be interested in
Weitere Informationen zum Thema "Medical Technology":
Gluon – KI-Entwicklung leicht gemacht
Die Deep-Learning-Schnittstelle Gluon (Open Source) ermöglicht es Entwicklern, schneller und einfacher Modelle für das Machine oder Deep Learning zu erstellen, ohne dass sich die Trainingsleistung ungebührlich verlängert. Gluon kann mit jeder beliebigen KI-Engine arbeiten.Weiterlesen